Results 51 to 60 of about 5,120 (192)

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

mAbs
The development of bispecific antibodies that bind at least two different targets relies on bringing together multiple binding domains with different binding properties and biophysical characteristics to produce a drug-like therapeutic.
Michael Mullin, James McClory, Winston Haynes, Justin Grace, Nathan Robertson, Gino van Heeke   +5 more
doaj   +1 more source

Intra-site differential inhibition of multi-specific enzymes

Journal of Enzyme Inhibition and Medicinal Chemistry, 2020
The ability to catalyse a reaction acting on different substrates, known as “broad-specificity” or “multi-specificity”, and to catalyse different reactions at the same active site (“promiscuity”) are common features among the enzymes.
Mario Cappiello, Francesco Balestri, Roberta Moschini, Umberto Mura, Antonella Del-Corso   +4 more
doaj   +1 more source

Identification of Mispairing Omic Signatures in Chinese Hamster Ovary (CHO) Cells Producing a Tri-Specific Antibody

Biomedicines, 2023
Monoclonal antibody-based therapy has shown efficacy against cancer, autoimmune, infectious, and inflammatory diseases. Multispecific antibodies (MsAbs), including trispecifics (tsAbs), offer enhanced therapeutic potential by targeting different epitopes.
Maria João Sebastião, Michael Hoffman, José Escandell, Fatemeh Tousi, Jin Zhang, Bruno Figueroa, Christine DeMaria, Patrícia Gomes-Alves   +7 more
doaj   +1 more source

Guiding the development of multispecific antibody-based cancer immunotherapies with 89Zr-immuno-PET imaging [PDF]

Antibody-based checkpoint inhibitors improved the treatment of patients with several tumor types. Several antibodies targeting immune checkpoints have been approved for the treatment of patients with cancers.
van Winkel, Claudia; id_orcid
core   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

MODELLING, SIMULATION AND VISUALIZATION OF A MULTISPECIFIC PHILIPPINE SEAGRASS MEADOW [PDF]

The International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences, 2019
Seagrass meadows are constantly under threat from natural and man-made stresses due to its shallow existence in the coastal environment. Restoration and preservation of seagrasses by means of rehabilitation or transplanting strategies is possible, but ...
V. P. Bongolan, G. M. Torres, J. E. Branzuela   +2 more
doaj   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Figure S3 from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors

, 2019
FIGURE S3: Transduced targets for testing of multispecific CARs.
Paula L. Kosasih (14985828), Stanley R. Riddell (14896908), Anusha Rajan (15002991), Qian Wu (209382), Michael C. Jensen (327373), Alexander I. Salter (15014123), Jenna Voutsinas (14933760), Andreas Plückthun (9240459), Ashwini Balakrishnan (15002976)   +8 more
core   +1 more source

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies

mAbs
Immunogenicity prediction is widely used in the developability assessment of antibodies, and many marketed and clinical-stage therapeutics have a predicted T-cell epitope in the second complementary-determining region of their light chain (CDR2L).
Maria U. Johansson, Anne Kerschenmeyer, Alessandra Carella, Simon Carnal, Yannik Schmidt, Alessandra de Felice, Dana Mahler, Marc Thomas, Fabio Mario Spiga, Julia Tietz, Christopher Weinert, Christian Hess, David Urech, Stefan Warmuth   +13 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source